Advertisement
Ear/Nose/Throat
Subscribe to Ear/Nose/Throat
View Sample

FREE Email Newsletter

Latest Information on Obese Patients with Type 2 Diabetes and LAP-BAND System

July 25, 2011 6:39 am | by Bio-Medicine.Org | News | Comments

LOS ANGELES, July 25, 2011 /- Bariatric surgery is recommended by IDF, the International Diabetes Foundation, for obese patients with type 2 diabetes. According to a new IDF position paper, bariatric surgeries for these obese patients can reduce health care costs in the long run....

Thermo Fisher licenses biomarker assays to Alere

July 21, 2011 9:46 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Life sciences equipment supplier Thermo Fisher Scientific Inc. today announced that it has signed a license agreement with Alere Inc. to add its BRAHMS biomarker assays to Alere's point-of-care Triage platform.

Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes

July 21, 2011 3:41 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., July 21, 2011 /- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.  ISIS-PTP1BRx is...

Advertisement

Solos Endoscopy's MammoView® System Proves Crucial to Early Breast Cancer Detection

July 20, 2011 6:43 am | by Bio-Medicine.Org | News | Comments

BOSTON, July 20, 2011 /- Solos Endoscopy, Inc.'s (OTCPK: SNDY) MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast...

FluMist® (Influenza Vaccine Live, Intranasal) Begins Shipping for 2011-2012 Influenza Season

July 18, 2011 10:51 am | by Bio-Medicine.Org | News | Comments

GAITHERSBURG, Md., July 18, 2011 /- MedImmune announced today that it has begun shipping FluMist® (Influenza Vaccine Live, Intranasal) to influenza vaccine distributors who service health care providers throughout the United States.   MedImmune expects to provide approximately...

Panacea Global, Inc. Signs Multi-year Contract Valued at Minimum $8.75 Million for Cancer Detection System with Palmverse Limited

July 12, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

ONTARIO, Canada, July 12, 2011 /- Panacea Global, Inc., ("the Company") (OTCQB: PANG), a biopharmaceutical company specializing in blood (protein), serum and tissue tests to diagnose and monitor cancer, today announced that it has signed a multi-year exclusive sales agreement with...

IDEV Technologies Launches Lower Profile SUPERA VERITAS® Stent Delivery System

July 12, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

WEBSTER, Texas, July 12, 2011 /- IDEV Technologies, Incorporated (IDEV), today announced the first procedures in Europe utilizing the new 6 French (6Fr) SUPERA VERITAS® Peripheral Vascular System.  The new lower profile delivery system offers physicians more treatment options,...

MedImage Cases™: A New Medical e-Textbook from Projects In Knowledge®

July 12, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

LITTLE FALLS, N.J., July 12, 2011 /- Projects In Knowledge ( www.projectsinknowledge.com ), the leading developer of cutting-edge digital and mobile information tools for busy clinicians, has just launched its newest free electronic medical textbook series: MedImage Cases, offered online...

Advertisement

High Precision Pressure Sensors in CPAP Respiratory Therapy Equipment

July 11, 2011 12:41 pm | by Dr. Adriano Pittarelli | Articles | Comments

Continuous Positive Airway Pressure (CPAP) machines are used to treat sleep apnea, a disorder that restricts breathing, and potentially causes stress to both the heart and circulatory system. Sensortechnics’ HDI and HCE series pressure sensors monitor the instantaneous pressure at the output of the machine and inside the breathing mask, increasing accuracy and sensitivity for individual CPAP users. 

Largest Multi-Centre Evaluation of Radioembolization Using Sir-Spheres for Patients With Inoperable Primary Liver Cancer Published in Hepatology

July 7, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

PAMPLONA, Spain, July 7, 2011 /-   Results of the multi-centre European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY) analysis of the long-term outcomes related to survival and safety of radioembolization using SIR-Spheres in patients with inoperable primary...

Council on Competitiveness Showcases Power of High Performance Computing in Case Study with GNS Healthcare

June 30, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, June 30, 2011 /PRNewswire-USNewswire/ -- The Council on Competitiveness, in partnership with the Defense Advanced Research Projects Agency (DARPA), is releasing a case study today highlighting the potential for high performance computing (HPC) to spur innovative solutions for...

A Wristwatch that Monitors Blood Pressure

June 29, 2011 8:32 pm | by Massachusetts Institute of Technology | News | Comments

Researchers hope a device that tracks vital signs around the clock will help patients better control their blood pressure.

The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients

June 28, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

ROCKVILLE, Md., June 28, 2011 /- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of...

Advertisement

New Test to Screen for Glaucoma Damage

June 21, 2011 7:45 am | by Bio-Medicine.Org | News | Comments

PINE BROOK, N.J., June 21, 2011 /- A recent paper published in the Journal of Glaucoma shows a new visual evoked potential (VEP) technique to be a fast, objective method to screen for functional damage in glaucomatous eyes. The technique, called short duration transient VEP (SD-tVEP),...

Maroon 5 Lead Singer Adam Levine Raises Awareness of Attention-Deficit/Hyperactivity Disorder in Young Adults and Adults With "Own It"

June 20, 2011 5:39 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, June 20, 2011 /- Adam Levine, lead singer of Maroon 5, is helping to raise awareness among young adults and adults about Attention-Deficit/Hyperactivity Disorder (ADHD) through a new national education campaign called "Own It" that launched today.  The campaign,...

American Medical Systems Announces Large-Scale, Physician-Led Registry of Penile Implants

June 15, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

MINNETONKA, Minn., June 15, 2011 /-   American Medical Systems® (AMS) (NASDAQ: AMMD ), a leading provider of world-class devices and therapies for male and female pelvic health, announced today the commencement of a major global registry of penile prosthetic outcomes.  The...

TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy

June 9, 2011 9:36 am | by Bio-Medicine.Org | News | Comments

SUNNYVALE, Calif., June 9, 2011 /- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that TomoTherapy shareholders have approved the proposed acquisition of TomoTherapy Incorporated (Nasdaq: TOMO ) by Accuray. More than 98 percent of votes...

New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS)

June 8, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

FRANKFURT, Germany, June 8, 2011 /- Merz Pharmaceuticals today announced that new data on Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the Movement Disorder Society's (MDS) 15th International Congress of...

Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure

June 8, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, June 8, 2011 /- Otonomy, Inc., a developer of innovative therapeutics for diseases and disorders of the ear, today announced positive results for OTO-201, a sustained release gel formulation of the antibiotic ciprofloxacin, in multiple preclinical studies evaluating the...

XTRAC Laser Provides New Hope for Children with Psoriasis

June 8, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

MONTGOMERYVILLE, Pa., June 8, 2011 /- About 20,000 children in the United States under the age of 10 are diagnosed with psoriasis every year. For many, the disease goes beyond painful red, dry patches of scaly, thickened skin; the emotional side-effects are equally life...

Edison Pharmaceuticals to Provide Expanded Access to EPI-743 for Mitochondrial Disease

June 7, 2011 11:32 pm | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., June 8, 2011 /- Edison Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has allowed an Expanded Access program to provide EPI-743 to seriously ill patients diagnosed with inherited respiratory chain diseases of the mitochondria....

The Premier Basketball League Brings on Key Health Industry Sponsorship for 2012

June 6, 2011 2:35 pm | by Bio-Medicine.Org | News | Comments

CHICAGO, June 6, 2011 /- The Premier Basketball League announced today that Scientific Imaginetics® , the global leader in non-invasive pain relief technology, has come on board as a corporate sponsor for the 2012 PBL season. Scientific Imaginetics' TMR® technology is a...

NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meetin...

June 4, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

CHICAGO and SAN FRANCISCO, June 4, 2011 /- Nektar Therapeutics (Nasdaq: NKTR ) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and third-line treatment in patients with metastatic breast cancer during the 2011 American Society...

Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia

June 3, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

CHICAGO, June 3, 2011 /- Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center today announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML). Data will be presented at the...

Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs)

June 2, 2011 1:33 pm | by Bio-Medicine.Org | News | Comments

SAN DIEGO, June 2, 2011 /- Biocept, Inc. today reported that its scientists and academic collaborators will present a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois June 3-7. The poster presentation is based on...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading